Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus zoledronic acid for prevention of skeletal-related events in men with castration-resistant prostate cancer and bone metastases
2006-000341-19Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and bone metastases comparing Denosumab with Zoledronic acid (2 arms). Primary endpoint: Time to first on-study skeletal-related event (non-inferiority). Started Mar 2006; status: completed.
02
Drugs
denosumabzoledronic acid
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2006-000341-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000341-19.